AGC (5201) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
5 Nov, 2025Executive summary
Net sales for the first nine months were ¥1,512.1 billion, down 1.4% year-over-year, with operating profit at ¥94.8 billion, up 0.9% year-over-year, and profit attributable to owners at ¥39.5 billion, a significant increase due to the absence of prior-year losses and impairments.
No change in the FY2025 full-year outlook from the August forecast, with net sales expected at ¥2,050 billion and operating profit at ¥120 billion.
Profit before tax improved significantly to ¥73.2 billion from a loss of ¥74.4 billion in the prior year, mainly due to the absence of large one-time losses related to the Russian business and prior impairments.
Financial highlights
Operating profit rose by ¥0.8 billion year-over-year, driven by improved product mix, pricing, and profit improvement measures, offset by higher raw material and fuel costs.
Free cash flow was ¥38.4 billion, with operating cash flow at ¥164.7 billion and investment cash flow at negative ¥126.4 billion.
CapEx totaled ¥174.1 billion, depreciation ¥132.6 billion, and R&D expenses ¥44.1 billion.
Cash and cash equivalents at period end were ¥99.7 billion, down from ¥107.9 billion at the start of the year.
Outlook and guidance
Full-year FY2025 guidance remains unchanged: net sales ¥2,050 billion, operating profit ¥120 billion, profit attributable to owners ¥57 billion, and basic EPS of ¥268.84.
Dividend per share for FY2025 is forecast at ¥210, with a stable policy targeting a DOE of about 3%.
Operating profit margin expected at 5.9%, ROE at 4.0%.
Fourth quarter sales are expected to be on par with Q3, but operating profit is projected to decline due to seasonality and segment-specific factors.
Latest events from AGC
- Operating profit and ROE improved; FY2026 targets higher growth led by Life Science recovery.5201
Q4 20256 Feb 2026 - Targets 8% ROE and 10% ROCE by 2026, focusing on growth, reforms, and sustainability.5201
IR Day 2024 Day 231 Jan 2026 - 8% ROE and 440bn yen EBITDA targeted for 2026 via transformation and disciplined investment.5201
IR Day 2024 Day 131 Jan 2026 - Targets net zero carbon by 2050, driven by innovation, ESG, and talent development.5201
ESG Update26 Sep 2025 - FY2025 outlook cut as Chemicals, Life Science, and Electronics underperform; profit rebounds.5201
Q2 20251 Aug 2025 - Global leader in glass, chemicals, and life sciences, driving innovation and sustainable growth.5201
Corporate Presentation7 Jul 2025 - Ambidextrous strategy and sustainability drive growth, digitalization, and profitability targets.5201
Company Presentation7 Jul 2025 - Life Science impairments and Russian exit led to a sharp H1 2024 net loss despite sales growth.5201
Q2 202413 Jun 2025 - Sales rose, but major impairments and Russian exit drove a sharp net loss.5201
Q3 202413 Jun 2025